Liver Diseases  >>  sofosbuvir/velpatasvir  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
sofosbuvir/velpatasvir / Generic mfg.
GS-US-342-0102, NCT01858766: Safety and Efficacy of Sofosbuvir + Velpatasvir With or Without Ribavirin in Treatment-Naive Adults With Chronic HCV Infection

Checkmark AASLD 2014
Oct 2014 - Oct 2014: AASLD 2014
Checkmark AASLD 2014
Oct 2014 - Oct 2014: AASLD 2014
Checkmark
More
Completed
2
379
US
SOF, GS-7977, PSI-7977, Sovaldi®, VEL, GS-5816, RBV, Ribasphere®
Gilead Sciences
Hepatitis C
05/14
08/14
GS-US-342-0109, NCT01909804: Safety and Efficacy of Sofosbuvir Plus Velpatasvir With or Without Ribavirin in Treatment-experienced Subjects With Chronic HCV Infection

Checkmark ILC 2015
Apr 2015 - Apr 2015: ILC 2015
Checkmark AASLD 2014
Oct 2014 - Oct 2014: AASLD 2014
Completed
2
323
US, RoW
SOF, Sovaldi®, GS-7977, PSI-7977, VEL, GS-5816, RBV, Ribasphere®
Gilead Sciences
Hepatitis C
05/14
08/14
LEPTON, NCT02202980: Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection

Completed
2
273
RoW
LDV/SOF, Harvoni®, GS-5885/GS-7977, RBV, SOF/VEL, Epclusa®, GS-7977/GS-5816, VOX, GS-9857
Gilead Sciences
Chronic Hepatitis C
03/16
05/16
NCT02300103: Efficacy And Safety Of Sofosbuvir/Velpatasvir Fixed Dose Combination With Ribavirin in Chronic HCV Infected Adults Who Participated in a Prior Gilead Sponsored HCV Treatment Study

Completed
2
69
US, RoW
SOF/VEL, GS-7977/GS-5816, Epclusa®, RBV
Gilead Sciences
Hepatitis C Virus Infection
07/16
09/16

Download Options